Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sun Pharma, Rockwell Medical Enter Licensing and Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sun Pharma, Rockwell Medical Enter Licensing and Supply Pact

Sun Pharma will be the exclusive development and commercialization partner for Rockwell's Triferic

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sun Pharmaceutical Industries’ subsidiary has entered into exclusive licensing and supply agreements with Rockwell Medical Inc. to commercialize Rockwell’s Triferic, a proprietary iron replacement and haemoglobin maintenance drug, for treating anaemia in hemodialysis patients in India. Triferic is approved in USA.

Sun Pharma will be the exclusive development and commercialization partner for Triferic during the term of the agreement. In consideration for the license, Rockwell will be eligible for upfront and milestone payments as well as a royalty on sales. Financial terms were not disclosed.

Kirti Ganorkar, chief executive officer of India business, Sun Pharma, said, “We are excited to build a partnership with Rockwell who has developed an innovative product, Triferic for haemodialysis patients. Triferic is an innovative anaemia therapy for patients who are undergoing haemodialysis and offers a unique treatment option. Triferic will help Sun Pharma expand its portfolio in its core therapy areas.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics